Review Article

DOI: http://dx.doi.org/10.18203/2349-3259.ijct20163955

Artificial intelligence in clinical research

Veerabhadra Sanekal Nayak*, Mohammed Saleem Khan, Bharat Kumar Shukla, Pranjal R. Chaturvedi

Department of Risk Based Monitoring, Tata Consultancy Services Ltd, Mumbai, Maharashtra, India

Received: 11 May 2016 Revised: 10 July 2016 Accepted: 11 July 2016

*Correspondence:

Mr. Veerabhadra Sanekal Nayak, E-mail: svnayak@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Envision dedicating fifteen years to a critical interest and emptying staggering amount of funds into it, at the same time confronting a disappointment rate of 95 percent. That is the crippling reality for pharmaceutical organizations, which toss billions of dollars consistently toward medications that possible won't work – and after that do a reversal to the planning phase and do it once more. Today's medications go to the business sector after an extensive, very costly process of drug development. It takes anywhere in the range of 10 to 15 years, here and there significantly more, to convey a medication from introductory revelation to the hands of patients – and that voyage can cost billions up to 12 billion, to be correct. That is just a lot to spend, and excessively yearn for patients to hold up. Patients can hardly wait 15 years for a lifesaving drug, we require another productive focused on medication revelation and improvement process. Artificial Intelligence, can significantly reduce the time included, and also cut the expenses by more than half. This is made conceivable through a totally distinctive way to deal with medication revelation. With the present technique, for each 100 medications that achieve first stage clinical trials, only one goes ahead to wind up a genuine treatment. That is stand out percent, it's an unsustainable model, particularly when there are ailments, for example, pancreatic malignancy which has a normal five-year survival rate of 6%.

Keywords: Artificial intelligence, Clinical trials, Information technology, Risk based monitoring, Drug development, Risk mitigation

INTRODUCTION

Majority of drugs take about 10 years or more to come to market, cost billions, and have a potential to even demolish an organization on an off chance that they might fail in late stage trials having poured in so much speculation. Venture forward artificial intelligence (AI); an idea turning out to be more essential in tending these issues and looking progressively like the fate of successful drug development.

May be the clearest utilization of counterfeit consciousness in pharma is utilizing its capacity to rapidly "perused" unlimited measures of logical information: research distributed in diaries, and also understanding records and tissue/blood tests, and utilizing designs as a part of the information to make experimental speculations which can coordinate pharma organizations' medication advancement. The rate of AI in these procedures permits organizations to create drugs taking into account natural markers, with more prominent exactness, instead of the scattergun methodology of concoction screening. Thus, organizations can focus on specific signs which the medication is well on the way to effectively treat. Something that would take human researchers weeks and months to break down, yet Watson (IBM's artificial intelligent supercomputer) can do likewise in a matter of minutes. Through machine learning, Watson and comparable system's show signs of improvement and speedier at the procedure through adva-

ncing their algorithms to incorporate new findings. Eventually, the screening procedure could be sufficiently quick to dissect the whole genome of every patient's individual malignancy and for medications to be customized taking into account its particular transformations, on the off chance that they exist. If not, there will be an organization keen on putting that privilege.



Figure 1: Artificial intelligence.

From the soonest crossroads in the cutting edge history of the PC, researchers have longed for making an 'electronic mind'. Of all the advanced mechanical missions, this inquiry to make misleadingly smart (AI) computer frameworks has been a standout amongst the most driven and, as anyone might expect, dubious. It likewise appears that at an opportune time, researchers and specialists alike were charmed by the potential such an innovation may have in prescription (eg. Ledley and Lusted, 1959). With clever computers ready to store and process unfathomable stores of learning, the trust was that they would get to be immaculate 'specialists in a crate', helping or surpassing clinicians with undertakings such as analysis. 1.2

With such inspirations, a little yet gifted group of computer researchers and social insurance experts start forming an exploration program for another control called Artificial Intelligence in Medicine (AIM). These analysts had a striking vision of the way AIM would alter medication, and push forward the boondocks of innovation.

Defining AIM is fundamentally worried with the development of AI projects that perform determination and make treatment proposals. Not at all like medicinal applications in view of other programming strategies, for example, have simply measurable and probabilistic techniques, and therapeutic AI projects depended on typical models of malady elements and their relationship to patient components and clinical indications.

Much has changed from that point forward, and today this definition would be viewed as thin in extension and vision. Today, the significance of determination as an errand requiring computer support in routine clinical circumstances gets substantially less accentuation. ³ So in spite of the centre of much early research on

understanding and supporting the clinical experience, master frameworks today will probably be discovered utilized as a part of clinical research centers and instructive settings, for clinical observation, or in information rich ranges like the serious consideration setting.¹

For its day, be that as it may, the vision caught in this meaning of AIM was progressive. After the primary rapture encompassing the guarantee of misleadingly clever indicative projects, the most recent decade has seen expanding frustrate amongst numerous with the potential for such frameworks. Yet, while there unquestionably have been continuous difficulties in growing such frameworks, they really have demonstrated their unwavering quality and precision on rehashed events.²

A great part of the trouble has been the poor path in which they have fitted into clinical practice, either tackling issues that were not saw to be an issue, or forcing changes in the way clinicians worked. What is currently being acknowledged is that when they fill a properly part, keen projects do for sure offer critical advantages. A standout amongst the most imperative assignments now confronting designers of AI based frameworks is to portray precisely those parts of medicinal practice that are most appropriate to the presentation of manmade brainpower frameworks.²

Managing the drug pipeline poses an enormous challenge to efficiently move through costly and time-consuming clinical trials as rapidly as possible. Every delay in the race to market means millions of dollars in lost revenues for a blockbuster drug.²

FEW EARLY ADOPTERS OF AI IN THE CLINICAL RESEARCH DOMAIN

Company named "MedRespond" is adding to a progression of projects highlighting the organization's patented custom conversation® to meet this test and streamline the clinical trial process. By consolidating Artificial Intelligence and streaming media, company permits clients to sort in their inquiries, in their own words, and the framework chooses the pre-recorded video that best answers their inquiries. At the point when new issues or inquiries emerge, the framework learns and adjusts. Utilizing this innovation, medicinal services suppliers can offer consistent backing to patients amid each period of a clinical trial.³

There are two parts of the project that company proposes creating.

Patient recruitment program

Company has worked with the University of Pittsburgh cancer canters to make a patient training program for disease clinical trials. The project is acquainted with recently analyzed growth patients at the centre. It highlights oncologists, scientists and patients noting questions about what it is similar to take part in a clinical trial, the shields that are set up to secure members and the consideration that is given amid a clinical trial. Growth patients and their families can utilize the project at the centre, or in the security of their own homes, day and night and around the globe.

As every patient investigates company's project and poses their questions, an itemized log is made to give precious understanding into the inquiries patients raise. An example report of data that can be caught is incorporated into this proposition. Through company's involvement in the disease clinical trial program, we have built up a sharp comprehension of what issues concern patients – symptoms, being dealt with like a guinea pig, accounts, family, notwithstanding stopping. Company additionally has involvement in serving to painstakingly make reactions that meet the unbending necessities of the IRB.³

Patient retention program

About 30% of clinical trial members drop out before the study is finished up. Consequently, once a patient has been enrolled, it is imperative that they be deliberately bolstered all through their trial interest. One reason for this dropout rate is an absence of continuous correspondence with the patient amid the trial, little appraisal of their status, and inability to advise them of trial advancement – all correspondence issues. Patients need to have consistent access to experts to answer their inquiries, evaluate their status and offer them some assistance with managing any issues or symptoms that they encounter. Customary answers for giving this backing depend on therapeutic staffing, an answer that is basically too unreasonable.³

Company's innovation empowers suppliers to recreate this ceaseless emotionally supportive network to give productive, and viable backing for clinical trial patients. Every week, the patient will visit the clinical trial checking site. A video host will affirm that the patient is sticking to the study convention and after that direct an online evaluation, particular to that patient and trial. Certain reactions could trigger further activity – alarming the doctor, asking for help, sending more data, or prescribing measurement alterations subsequent to counselling with the study doctor. The framework likewise may prescribe how to get ready for the following centre visit.

This correspondence connection to the clinical trial patient will likewise be utilized to overhaul members about the status of their trial or instruct them concerning any issues. Patients will really feel just as their data is esteemed and that they are in effect deliberately observed and kept informed as the trial continues, something that

happens every once in a while in today's clinical trial process.³

PRECISION MEDICINE AN AI APPROACH

Precision remedy which is getting the right treatment to the right patient at the ideal time. Remembering the finished objective to truly appreciate the disorder and how to treat it, the full natural make-up of the phone. This joins the genome, proteome, lipidome, metabolome. It can in like manner be looked upon mitochondrial limit, oxidative states, and ATP creation, as how the cell is acting. ^{4,5}

Examination of illness cells routinely takes years – yet the superbness of fake awareness is that it works speedier than any human could. In business part there are diverse associations who are wearing down Artificial Intelligence, for occasion Berg it takes tests of blood, pee and tissue from illness patients and complexities those examples and those from sound patients. More than 14 trillion data centers are produced using this method. The dominant part of that data is then supported into fake cognizance systems.

The AI separates most of the information from the patient's science including OMICS, clinical illustrations, and demographics to offer us some help with comprehension the complexity between the sounds and wiped out cells. Once the cognizance of wiped out cells is expert then, wear down how to make the cells strong again can be proficient by method for AI. 4.5

Each one of that examination is so mind boggling and wide that it would take individuals a lifetime to complete it. With the help of AI, all that data is crunched in the scope of days or weeks, obtaining profitable time in the pharmaceutical creation process. The result is a centered around treatment, specially crafted to the individual, considering their own body's beauty care products.

FOURTH INDUSTRIAL REVOLUTION: AI

Numerous have authored that world is amidst the fourth industrial revolution where we are at the tipping purpose of an entire assortment of interconnected innovation leaps forward: robots, rambles, shrewd urban areas, computerized reasoning, and cerebrum research. By, the fourth industrial revolution is not an item unrest; it is a framework insurgency.^{6,7}

We live in reality as we know it where we are overpowered with advancement and innovation leaps forward in counterfeit consciousness, associated gadgets (the internet of things), 3D printing, self-driving vehicles, consistent availability and vast figuring power. These advancements are changing the world in a significant and eccentric path and at a much quicker rate than any time in recent memory. The sheer volume of advancements and

the rate of progress is overwhelming. It will definitely drive a wholesale change of organizations and procedures as we probably am aware them today. Human services and pharmaceutical businesses are no exemption and maybe give one of the greatest open doors for a positive effect. Here are three ways that clinical trials will be changed by the Fourth Industrial Revolution. ^{6,7}

PATIENTS WILL BE DYNAMIC MEMBERS IN THE CLINICAL TRIAL

By far most of clinical trials today are led without direct information from patients as most information are gathered by human services suppliers amid patient visits. In any case, billions of individuals are as of now conveying associated individualized computing gadgets (advanced cells and tablets) and billions more will be associated through wearable gadgets soon. This gives the chance to catch information specifically from patients in a continuous and convenient way as they enter that data on their own cell phones. Even better, information for non-transferable ailments, for example, hypertension and diabetes can be caught and transmitted straightforwardly through wearable medicinal gadgets. Accordingly, the information caught will be significantly more point by point and of higher quality in this manner expanding the pace and viability of clinical trials.

Clinical trials systems will consistently facilitate all parts of the trial

Envision an EDC or eCOA framework that is associated with the IVRS framework which tracks the investigational item progressively empowered by the IoT base. These associated frameworks will permit situations, for example, planning the patient visit in light of the accessibility of the investigational item. Clinical Trial Systems will move into the cloud and will be able to correspond with individuals, different frameworks, gadgets and supplies by means of backing of standard conventions, for example, SAML and Oauth for security and personality administration, distributed API for combination, and implicit work process motors for arrangement. These frameworks will consistently associate individuals, offices, hardware and supplies progressively to empower more proficient and viable clinical trials.

Crowd sourcing will change trial interest

For pharmaceutical organizations, joining examiners and patients for clinical trials is a period expending and costly process that depends intensely on whom you know and the amount of cash you spend on customary media and selection representatives. On the other side, agents and patients have couple of alternatives and no dependable hotspots for what clinical trials they can take part in. Cloud based clinical trial frameworks will make publishing so as to agree to trials straightforward web posting of accessible clinical trials and registries of

examiners and patients. Specialists and patients will have the capacity to distribute and share the accreditations and vitals effectively and safely through frameworks that will impart only the data they approve to the right gatherings. While we don't know precisely to what extent it will take for the Fourth Industrial Revolution to totally change clinical trials, we can be sure that change is unavoidable. For dynamic associations and business people, this introduces a huge chance to enhance existing arrangements and benefits or make totally new offerings. For others, it will be important to adjust to these progressions just to survive.

FUTURE OF AI

The firmly controlled medicinal services industry has made little utilization of counterfeit consciousness in this way. One of the issues has dependably been that social insurance is excessively mind boggling. Keeping in mind the end goal to foresee anything around one's wellbeing, we require data on demographics, proteins, multi-quality cooperation's, ecological impacts, and an entire host of different features. Those conceivable outcomes are startling and energizing.

AI TO PREDICT DRUG RESISTANCE

Could AI foresee human services results? Specialists are chipping away at approaches to utilize AI and machine figuring out how to anticipate reactions from two chemotherapy medicines used to treat breast cancer patients.

The fundamental issue is that not everybody with the same growth reacts similarly. Computerized reasoning is an effective apparatus to anticipate drug results since it takes a gene at the entirety of all the collaborating qualities. They discovered it was conceivable to foresee which patients with breast cancer malignancy would encounter upgrades when utilizing the medication Paclitaxel.

HOW AI COULD BOLSTER PHARMACEUTICAL ADHERENCE

Can AI check whether we took our pills? Per reports, an organization in the US does precisely that. AI Cure is a start-up that uses artificial intelligence on patient's cell phones to affirm solution ingestion support in clinical trials and high-chance populaces. How can it work? AI Cure's HIPAA-agreeable programming catches and dissects proof of drug ingestion. A cell phone's camera is utilized to comprehend whether patients took the medicine effectively. ¹⁰

Ongoing information is likewise unified for quick mediation and longitudinal following of adherence examples. Research found that patient non-adherence to recommended medicines is connected with poor restorative results, movement of malady, and causes billions of dollars every year in avoidable direct human services costs. Presently, social insurance experts just need to guarantee that each patient makes utilization of his or her cell phone.

AI for smarter drug development

IBM Watson is presumably a standout amongst the most surely understood samples of a supercomputer that has demonstrated its capacities in AI past the lab. Other than noting questions for the test show Jeopardy, Watson is likewise ready to comprehend and extricate key data by looking through a large number of pages of exploratory restorative writing and afterward picture connections in the middle of medications and other potential infections.

A year ago, IBM declare that the pharmaceutical mammoth Johnson and Johnson and contender Sanofi would participate in a joint effort with IBM Watson's Discovery Advisor group. J&J will likely educate the supercomputer to peruse and comprehend experimental papers that contain clinical trial results, and afterward create and assess medicines and different medications. While this may not sound excessively energizing, it could have inconceivable outcomes on how pharmaceutical organizations do similar viability examines.¹¹ The IBM proclamation recommends that it could help specialists to coordinate a medication with the right arrangement of patients keeping in mind the end goal to expand adequacy and minimize symptoms. This would be distinctive to the manual process at present connected, which obliges months to discover information and proof before a study can even begin.

The utilization of Watson could essentially decrease the time, and subsequently quicken the procedure of disclosure. It was reported this was the principal open declaration of pharmaceutical organizations to grasp a supercomputer's capacities and use it for prescient investigation towards drug improvement.

AI for Alzheimer's patients

A venture led at the University of Washington and its branch of computer science investigated the utilization of AI frameworks to backing and improve the freedom and personal satisfaction of Alzheimer's patients. Such helped discernment frameworks would make utilization of AI innovation to supplant a percentage of the memory and critical thinking capacities that have been lost by an Alzheimer's patient. By scientists, the inspiration for this undertaking comes from the need to advance the prosperity and freedom of individuals experiencing intellectual constraints because of maturing and Alzheimer's ailment.¹²

AI for wearable health

An issue with internet of things (IoT) applications has been the means by which to make utilization of their

information, as PCs immediately achieved a breaking point of what should be possible with every one of that was gathered. Thankfully, machine-learning frameworks have adjusted to handle bigger limits of approaching information. Zulfi Alam, general director for individual gadgets at microsoft, clarifies in a post that their brilliant forthcoming calculations will know enough about the client and her biometrics in a consistent state to have the capacity to perceive examples and chances to enhance client wellbeing and wellness.

In a more basic human services setting, an exploration group at the university of California, Los Angeles, proposes a stage for wellbeing observing utilizing remote sensor systems. The stage's engineering is a system empowered framework that backings different wearable sensors and contains on-board general figuring abilities for executing separately customized occasion discovery, cautions, and system correspondence with different restorative informatics administrations. ¹³

Envision this checking stage associated with computerized reasoning and machine learning abilities, and the way we deal with patients later on could essentially change.

FUTURE OF AI IN CLINICAL RESEARCH/HEALTHCARE

Healthcare professionals seem to be skeptical about the use of artificial intelligence in their practice. Above we presented a few use cases where AI could add value to healthcare, especially in areas where it could excel beyond the abilities of humans. Yet, AI is still in an infant stage of development and will not be able to replace a doctor. The big question we may want to ask is, 'how can machine learning become a greater enabler for healthcare and its participating players?.' The time is right to ask doctors and pharmaceutical companies what problems they have, and how AI could help solve them.

AI is a study acknowledged to imitate human knowledge into PC innovation that could help both specialists and patients in the accompanying way:

- By giving a research facility to the examination, representation, and classifying of restorative data.
- By concocting novel devices to bolster choice making and research.
- By incorporating exercises in medicinal, programming and psychological sciences lastly.
- By offering a substance rich order for future logical restorative group.

Along these lines, expanded combination of insightful AI devices in regular medicinal applications could enhance the effectiveness of medications and stay away from expenses by minimizing the dangers of false determination, encourage more focused on pre-agent

arranging, and decrease the danger of intra-agent entanglements. The late use of AI in performing advanced undertakings and calculations has step by step driven it to be presented as a key part of MRI and figured tomography frameworks. The additional point of preference of these frameworks is in the capacity to adequately procure data, and sync with set up choice bolster databases. Further, AI has started changing the field of surgical mechanical technology wherein it has empowered the appearance of robots that perform semirobotized surgical errands with expanding effectiveness. One of a definitive difficulties confronted in mechanical autonomy could be imitating of human knowledge and body movement. Despite such a basic test, mechanical autonomy has achieved impressive advance and is presently connected over a wide cluster of utilizations extending from the guard business to the diagnostics. Essentially, robots are not assembled insightfully, but rather are coordinated with certain product segments to make them smart. Late advances in the field of AI, for example, neural systems administration, normal dialect preparing, picture acknowledgment, and discourse acknowledgment/combination research, have impelled our imagination and the eventual fate of mechanical technology looks brilliant in reality.

It merits specifying here that the greatest obstacle towards selection of medicinal mechanical surgical frameworks is the high beginning capital gear costs included. A large number of these frameworks regularly require new base to be built and the staffing of high bill rate pros who are all around prepared in these procedures develops to be a key impediment in its far reaching reception. An essential AI PC utilized today as a part of clinical practice could be pictured to be connected for robotization of routine undertakings and for different capacities recorded beneath:

Alerts and updates in most broad types of AI coordination, the machine examines a patient's lab results, drug requests, and redesigns the patient with a fitting update. In this way to generate cautions and updates, more propelled AI projects can be specifically interfaced with a patient screen and utilized for distinguishing changes as a part of a patient's condition. ¹⁵

- Therapy fore-arranging specific conditions that require elaborate treatment arrangements could profit by AI instruments amid treatment arranging. By consolidating an AI framework that can naturally detail arranges in view of particular conditions would increase the value of the doctors and also patients.
- Information retrieval similarly, programming hunt specialists can be made down complex medicinal applications that are substantially more proficient than current era web-slithering operators' execution. This guides in data recovery and up-gradation of information naturally.

 Image interpretation multiple medicinal pictures can be promptly distinguished, from plane X-beams through to very mind boggling pictures like angiograms, CT, and MRI examines. Such frameworks for picture acknowledgment and translation have progressively been received for clinical use.

Another key utilization of AI frameworks is presently experimental exploration through applying master frameworks and choice emotionally supportive networks. Such frameworks are customized to learn, i.e. to total and hold limitless measures of designed information for particular purposes. Today, DSS innovation has been effectively utilized in the medicinal gadget industry that includes heart checking and robotized ECG, therapeutic imaging, clinical research centre investigation, respiratory observing, electroencephalography, and anesthesia.

CONCLUSION

Man-made brainpower (AI) innovations have made huge advances and a stream of companies are focusing, applying these advances to business challenges and, all the while, pioneering new trails. While numerous individuals might consider computerized reasoning as something recondite and in the domain of sci-fi, there are genuine applications that can offer organizations some assistance with solving complex issues, for example, understanding enormous information, increasing human choice making, or furnishing clients with master guidance.

The time is ready for AI innovations. This is a direct result of the phenomenal size of registering and capacity limits, where preparing power, distributed computing and rapid stockpiling are accessible at reasonable costs. This takes into consideration complex calculations to be accomplished in seconds, instead of weeks. Manmade brainpower is characterized by Forrester as the hypothesis and abilities that endeavour to copy human knowledge through experience and learning. AI abilities incorporate elaborate thinking models to answer unpredictable inquiries and take care of complex issues. In the venture space, engineers are beginning to utilize AI to construct subjective figuring frameworks. AI is developing quick in this decade, and Forrester predicts it will turn out to be a piece of the everyday engagement of clients with PCs, gadgets, wearable's and frameworks we interface with to complete errands, get answers, get support in settling on choices and robotize dull activities. AI should eventually drive business development to offer endeavours some assistance with bettering serve their clients, he includes, which makes for a solid driver of appropriation in the undertaking space. AI advancements are accessible for different markets and parts, and offer five consumable business abilities. A third region is instinctive correspondence, going past basic voice acknowledgment and characteristic dialect handling, looking so as to permit the catch of the genuine importance at the semantics of content and discourse, by mapping outward appearances and signals to enthusiastic state and mapping voice inflection to passionate state. AI can likewise empower organizations to take a gander at far reaching, complex and curated information, mine it, and naturally create a smart and instinctive story out of it, or to make inferences or propose proposals in view of the investigation.

Funding: No funding sources Conflict of interest: None declared Ethical approval: Not required

REFERENCES

- 1. Pixabay Image source. 2015. Available at https://pixabay.com/en/header-banner-head-display-dummy-915122/. Accessed 02 March 2016.
- 2. Artificial Intelligence in Medicine: an Introduction. 2004. Available at http://www.openclinical.org/aiin medicine.html. Accessed on 02 March 2016.
- 3. Clinical Trials AI. 2015. Available at http://www.m edrespond.com/technology/pharmaceutical/clinical-trials. Accessed on 02 March 2016.
- 4. Shortliffe EH. The adolescence of AI in medicine: will the field come of age in the '90s?. Artif Intell Med. 1993;5(2):93106.
- Coiera E, Baud R, Console L, Cruz J, Durinck J, Frutiger P, et al. The Role of Knowledge Based Systems in Clinical Practice. In: Barahona and Christenen eds, Knowledge and Decisions in Health Telematics The Next Decade. Amsterdam: IOS Press; 1994: 199-203.
- Clancey WJ, Shortcliffe EH. Readings in Medical Artificial Intelligence: the First Decade Reading, MA: Addison Wesley; 1984.
- Baxt WG. A neural network trained to identify the presence of myocardial infarction bases some decisions on clinical associations that differ from

- accepted clinical teaching. Med Decision Making. 1994;14:217-22.
- Cross SS, Harrison RF, Kennedy RL. Introduction to neural networks. Lancet. 1995;346:1075-9.
- 9. Baxt WG. Application of artificial neural networks to clinical medicine. Lancet. 1995;346:1135-8.
- 10. Burke HB, Goodman PH, Rosen DB, Henson DE, Weinstein JN, Harrell FE Jr, et al. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer. 1997;79:857-62.
- 11. Lee SD. Biotech startup hope to cure cancer with AI. 2015. Available at http://hitconsultant.net/2015/11/10/this-biotech-startup-hopes-to-cure-cancer with-artificial-intelligence. Accessed on 02 March 2016.
- 12. Borukhovich E. How will artificial intelligence change in healthcare. 2015. Available at http://www.weforum.org/agenda/2015/10/how-will-artificial-intelligence-change-healthcare. Accessed on 02 March 2016.
- Bruce A, Hinshaw D. Artificial Intelligence perspectives on the acute care. 2015. Available at http://www.cepamerica.com/news-resources/perspec tives-on-the-acute-carecontinuum/2015-december/ most-popular-2-artificial-intelligence. Accessed on 02 March 2016.
- 14. Kannan PV. Artificial Intelligence. 2016. Available at http://www.asianhhm.com/technologyequipment/artificial-intelligence. Accessed on 02 March 2016.
- 15. Tao AL. How artificial intelligence AI is be used by Asean business. 2015. Available at http://www.com puterweekly.com/ news/4500251390/How-Arificial-intelligence-AI-is-being-tested-by-Asean business. Accessed on 02 March 2016.

Cite this article as: Nayak VS, Khan MS, Shukla BK, Chaturvedi PR. Artificial intelligence in clinical research. Int J Clin Trials 2016;3(4):187-93.